Clinical trials: sponsored by Dana-Farber Cancer Institute
Carcinoma, Squamous Cell of Head and Neck, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck
This research study is evaluating a drug called buparlisib (BKM120) as a possible treatment for locally advanced head and neck squamous cell cancer.
- Conditions
- Carcinoma, Squamous Cell of Head and Neck, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Hypopharyngeal Cancer, Early Invasive Cervical Squamous Cell Carcinoma
- Trial name
- NCT02113878
- Testing
- BKM120, Cisplatin, Intensity-modulated radiotherapy (IMRT)
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Dana-Farber Cancer Institute
Chronic Lymphocytic Leukemia, Richter Syndrome
Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS
This research study is assessing a new drug, duvelisib, in combination with a drug that is already FDA approved, venetoclax, as a possible treatment for participants with CLL or those with Richter's Syndrome
- Trial name
- NCT03534323
- Testing
- Duvelisib, Venetoclax
- Where
- 7 sites in United States
- Volunteers
- 55 people
- Sponsor
- Dana-Farber Cancer Institute
Chronic Lymphocytic Leukemia
A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL
This research study is evaluating a new drug called IPI-145 in combination with the standard drugs fludarabine, cyclophosphamide, and rituximab (FCR), as a possible treatment for chronic lymphocytic leukemia (CLL).
- Trial name
- NCT02158091
- Testing
- IPI-145, Fludarabine, Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Dana-Farber Cancer Institute
Malignant Rhabdoid Tumor, Rhabdoid Tumor of the Kidney
Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers
This clinical trial is studying two immunotherapy drugs (nivolumab and ipilimumab) given together as a possible treatment for INI1-negative tumors.
- Conditions
- Malignant Rhabdoid Tumor, Rhabdoid Tumor of the Kidney, Epithelioid Sarcoma, Chordoma (Poorly Differentiated or De-differentiated)
- Trial name
- NCT04416568
- Testing
- Nivolumab, Ipilimumab
- Where
- 8 sites in United States
- Volunteers
- 30 people
- Sponsor
- Dana-Farber Cancer Institute
Cancer, Quality of Life
The PRISM Intervention: a Multi-site Randomized Controlled Trial for Adolescents and Young Adults With Advanced Cancer
Multi-Site Randomized Controlled Trial testing the efficacy of the Promoting Resilience in Stress Management (PRISM) intervention among Adolescents and Young Adults with Advanced Cancer
- Conditions
- Cancer, Quality of Life, Anxiety, Depression
- Trial name
- PRISM-AC (NCT03668223)
- Testing
- Promoting Resilience in Stress Management (PRISM)
- Where
- 5 sites in United States
- Volunteers
- 269 people
- Sponsor
- Dana-Farber Cancer Institute
Cancer Prevention, Weight Loss
PROFAST Intervention in Precursor Multiple Myeloma
This is a 4-month randomized trial of a prolonged nightly fasting intervention (PROFAST) in 40 overweight and obese individuals with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM)…
- Conditions
- Cancer Prevention, Weight Loss, Smoldering Waldenstrom Macroglobulinemia(WM), MGUS
- Trial name
- PROFAST (NCT05565638)
- Testing
- Prolonged Fasting Intervention, EDUCATION CONTROL
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Dana-Farber Cancer Institute
HER-2 Positive Breast Cancer, Breast Cancer
T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA
This research study is studying a combination of drugs as a possible treatment for breast cancer that has tested positive for a protein called HER2.
- Conditions
- HER-2 Positive Breast Cancer, Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer
- Trial name
- NCT02326974
- Testing
- T-DM1, Pertuzumab, Excision of tumor/mastectomy
- Where
- 4 sites in United States
- Volunteers
- 164 people
- Sponsor
- Dana-Farber Cancer Institute
Stage I Breast Cancer, Stage II Breast Cancer
Niraparib + Dostarlimab In BRCA Mutated Breast Cancer
This research study involves pre-operative therapy that is specifically targeted for breast cancer in individuals with BRCA and PALB2 mutations.
- Conditions
- Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, Breast Cancer
- Trial name
- NCT04584255
- Testing
- Niraparib, Dostarlimab
- Where
- 8 sites in United States
- Volunteers
- 66 people
- Sponsor
- Dana-Farber Cancer Institute
Osteosarcoma, Osteosarcoma Recurrent
Olaparib With Ceralasertib in Recurrent Osteosarcoma
This study is being done in order to evaluate the effectiveness of using two drugs (olaparib and ceralasertib) to treat patients with osteosarcoma that has not responded to treatment or has come back after treatment The names of…
- Trial name
- NCT04417062
- Testing
- Olaparib, Ceralasertib
- Where
- 4 sites in United States
- Volunteers
- 49 people
- Sponsor
- Dana-Farber Cancer Institute
Chronic Lymphocytic Leukemia
A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
This research study is evaluating a combination of two drugs, ibrutinib and obinutuzumab, as a possible treatment for Chronic Lymphocytic Leukemia (CLL).
- Trial name
- NCT02537613
- Testing
- Obinutuzumab, Ibrutinib
- Where
- 4 sites in United States
- Volunteers
- 52 people
- Sponsor
- Dana-Farber Cancer Institute
Hodgkin Lymphoma, Relapsed Hodgkin's Disease, Adult
Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL
This study is looking at the effects of Ipilimumab when it is given alone or in combination with Nivolumab to patients with relapsed or refractory classic Hodgkin's lymphoma (cHL).
- Conditions
- Hodgkin Lymphoma, Relapsed Hodgkin's Disease, Adult, Refractory Hodgkin Lymphoma
- Trial name
- NCT04938232
- Testing
- Nivolumab, Ipilimumab
- Where
- 4 sites in United States
- Volunteers
- 13 people
- Sponsor
- Dana-Farber Cancer Institute
Metastatic Breast Cancer
Palbociclib After CDK and Endocrine Therapy (PACE)
This research study is studying three combinations of drugs as treatments for breast cancer. The drugs involved in this study are: Fulvestrant Fulvestrant with Palbociclib Fulvestrant with Palbociclib and Avelumab
- Trial name
- NCT03147287
- Testing
- Palbociclib, Fulvestrant, Avelumab
- Where
- 22 sites in United States
- Volunteers
- 220 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer
Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer
This research study is studying a drug called Carboplatin with or without another study drug, Nivolumab as a possible treatment for triple-negative breast cancer that has spread to other parts of the body.
- Trial name
- NCT03414684
- Testing
- Carboplatin, Nivolumab
- Where
- 10 sites in United States
- Volunteers
- 78 people
- Sponsor
- Dana-Farber Cancer Institute
Glioblastoma
A Study of Abemaciclib in Recurrent Glioblastoma
This research study is studying a targeted therapy as a possible treatment for recurrent glioblastoma (GBM). The following intervention will be used in this study: -Abemaciclib
- Trial name
- NCT02981940
- Testing
- Abemaciclib, Surgery
- Where
- 7 sites in United States
- Volunteers
- 45 people
- Sponsor
- Dana-Farber Cancer Institute
Advanced Breast Cancer, Anxiety
RCT of CBD for Anxiety in Advanced Breast Cancer
This research study is investigating use of a single dose of cannabidiol (CBD) to help manage anticipatory anxiety in participants with advanced breast cancer poised to undergo computed tomography (CT) or positron emission…
- Conditions
- Advanced Breast Cancer, Anxiety, CBD
- Trial name
- NCT04482244
- Testing
- Cannabidiol
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Dana-Farber Cancer Institute
Thyroid Cancer
RAD001 for Patients With Radioiodine Refractory Thyroid Cancer
Since thyroid cancer becomes refractory to radioactive iodine, treatment options are very limited. Tyrosine kinase inhibitors such as sorafenib have recently shown promise.
- Trial name
- NCT00936858
- Testing
- RAD001
- Where
- 4 sites in United States
- Volunteers
- 50 people
- Sponsor
- Dana-Farber Cancer Institute
Thyroid Cancer
A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer
This research study is studying a targeted therapy as a possible treatment for thyroid cancer. A targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific types of cancer cells…
- Trial name
- NCT02657551
- Testing
- Regorafenib
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Dana-Farber Cancer Institute
Lymphoma, Histiocytic Sarcoma
Pembrolizumab in Neoplasms or Lymphomas
This research study is studying a drug called pembrolizumab as a possible treatment for aggressive lymphoma or a histiocyte or dendritic cell neoplasm. The drug involved in this study is: -Pembrolizumab
- Conditions
- Lymphoma, Histiocytic Sarcoma, Follicular Dendritic Cell Sarcoma, Interdigitating Dendritic Cell Sarcoma
- Trial name
- NCT03316573
- Testing
- Pembrolizumab
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Dana-Farber Cancer Institute
Recurrent, Refractory, or High Risk Leukemias, Matched Targeted Therapy
Matched Targeted Therapy For High-Risk Leukemias and Myelodysplastic Syndrome
This research study is seeking to gain new knowledge about Recurrent, Refractory, or High Risk Leukemias in children and young adults. This study is evaluating the use of specialized testing called leukemia profiling.
- Trial name
- NCT02670525
- Testing
- Leukemia Profiling
- Where
- 15 sites in United States
- Volunteers
- 338 people
- Sponsor
- Dana-Farber Cancer Institute
Drug/Agent Toxicity by Tissue/Organ, Leukemia
05-001: Treatment of Acute Lymphoblastic Leukemia in Children
RATIONALE: L-asparaginase is an important component of treatment for childhood acute lymphoblastic leukemia, but is also associated with notable side-effects, including hypersensitivity, pancreatitis, and thrombosis.
- Trial name
- NCT00400946
- Testing
- asparaginase, cyclophosphamide, cytarabine
- Where
- 8 sites in United States, Canada
- Volunteers
- 800 people
- Sponsor
- Dana-Farber Cancer Institute